
EKSO Stock Forecast & Price Target
EKSO Analyst Ratings
Bulls say
Ekso Bionics Holdings Inc. demonstrated significant financial recovery in the third quarter of 2025, reporting total revenues of $4.22 million, a remarkable increase of 105% quarter-over-quarter, alongside improved gross margins of 60.3%. The sequential growth in revenues indicates a potential rebound from previous challenges, suggesting that earlier delays may have been unique to that period. Additionally, the company's strategic move to enter a non-binding merger agreement with Applied Digital Cloud highlights its commitment to growth and innovation in the exoskeleton market.
Bears say
Ekso Bionics Holdings Inc experienced a revenue miss in the prior quarter, attributed to two significant order delays totaling $1.5 million, which raises concerns about the reliability of its enterprise sales segment. The company's reported revenues for 3Q25 were $4.23 million, slightly above consensus estimates, but the net loss per share of $0.54 indicates ongoing financial challenges. Furthermore, the removal of the previous price target and downgrade to Neutral reflects a general lack of confidence in the company's ability to achieve consistent growth and profitability in the near term.
This aggregate rating is based on analysts' research of Ekso Bionics Hlds and is not a guaranteed prediction by Public.com or investment advice.
EKSO Analyst Forecast & Price Prediction
Start investing in EKSO
Order type
Buy in
Order amount
Est. shares
0 shares